TITLE

IN THE PIPELINE

PUB. DATE
February 2001
SOURCE
Drug Utilization Review;Feb2001, Vol. 17 Issue 2, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Presents updates on clinical trials in the United States (U.S.). Details on the clinical trials initiated by AeroGen Inc. for its insulin inhaler; Completion of Alliance Pharmaceutical Corporation's clinical trial on its intrapulmonary agent perflubron; Result of the clinical trial conducted by Cell Genesys Inc. on its prostate cancer vaccine.
ACCESSION #
4184981

 

Related Articles

  • Alliance Ends Testing on Its LiquiVent Product. Webb, Marion // San Diego Business Journal;5/28/2001, Vol. 22 Issue 22, p9 

    Reports failure in the clinical trials for the drug LiquiVent of Alliance Pharmaceuticals Corp. in San Diego, California. Use of the drug in treating acute respiratory distress syndrome breath; Decision of the company to pursue the development of the drug; Impact of the failed clinical trials...

  • AFO 150: Imagent, Imavist.  // Drugs in R&D;2002, Vol. 3 Issue 2, p116 

    Adis Comments AFO 150 [Imavistâ„¢] consists of perfluorochemical-based microbubbles and is being developed by Alliance Pharmaceutical Corporation in the USA. AFO 150 is an ultrasound contrast agent with use in cardiac function and perfusion, and as an enhancer of the images of prostate,...

  • Aerogen gains approval for entry into Chinese market.  // Medical Device Daily;2/21/2012, Vol. 16 Issue 34, p1 

    The article reports on the authorization obtained by device and drug delivery company Aerogen to sell its Aeroneb Pro and Aeroneb Go products in China.

  • ALLIANCE PLANS EUROPEAN PHASE 3 STUDY FOR OXYGENT.  // Worldwide Biotech;May2002, Vol. 14 Issue 5, p3 

    Reports on the announcement of Alliance Pharmaceutical Corp. that representatives from Alliance and Baxter Healthcare Corp. have met with selected European regulatory authorities to review the clinical development plans for the intravascular oxygen carrier Oxygent.

  • Big lift for biomeds; FDA gives Alliance drug OK. Fikes, Bradley J. // San Diego Business Journal;8/23/93, Vol. 14 Issue 34, p5 

    Reports on the Food and Drug Administration's approval of a diagnostic drug produced by Alliance Pharmaceutical Corp. Imagent GI, a contrast agent for magnetic resonance imaging pictures of the bowel; Sales estimates; Market for temporary blood substitutes and cell oxygenator; Effect on San...

  • Alliance Pharmaceutical Corp.  // San Diego Business Journal;11/1/93, Vol. 14 Issue 44, Business action p1A 

    Introduces Alliance Pharmaceutical Corp.'s products based on perfluorochemicals. Temporary red blood cell substitute called Oxygent; `Liquid breathing' drug called LiquiVent; Oral contrast agent called Imagent GI; More.

  • OXYGENT REDUCES NEED FOR DONOR BLOOD IN PHASE 3 STUDY.  // Biotech Business;Oct2000, Vol. 13 Issue 10, p4 

    Reveals the results of a study citing that Oxygent from Alliance Pharmaceutical Corp. was found to significantly reduce the need for donor blood in patients undergoing surgical procedures.

  • Mixing medicines at Alliance. Hasenfuss, Marc // Finance Week;10/25/2002, p28 

    Analyzes the business performance of South African drug firm Alliance Pharmaceuticals, a subsidiary of Forim Holdings. Continued decline of Alliance under the leadership of chief executive Meyer Gelbart; Possible growth of Alliance with a stronger involvement from shareholders Thebe Healthcare...

  • A dose of good medicine. Hasenfuss, Marc // Finance Week;6/9/2003, p29 

    Looks at the prospects for South Africa-based Alliance Pharmaceutical Corp. for the second half of 2003. Emergence of a consortium led by Thebe and healthcare expert Ian Black; Shareholders' contention that management consistently underperformed its performance mandate; Trading margins; Cash...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics